Tredje AP fonden Has $2.84 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Tredje AP fonden trimmed its stake in Hologic, Inc. (NASDAQ:HOLX) by 1.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,191 shares of the medical equipment provider’s stock after selling 589 shares during the period. Tredje AP fonden’s holdings in Hologic were worth $2,836,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Massmutual Trust Co. FSB ADV raised its stake in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares in the last quarter. Graypoint LLC lifted its holdings in shares of Hologic by 3.9% during the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock worth $302,000 after acquiring an additional 147 shares during the period. Sequoia Financial Advisors LLC boosted its position in shares of Hologic by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after acquiring an additional 165 shares in the last quarter. Parallel Advisors LLC increased its stake in Hologic by 11.5% in the fourth quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock valued at $131,000 after acquiring an additional 189 shares during the period. Finally, Cambridge Investment Research Advisors Inc. raised its position in Hologic by 0.6% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 31,112 shares of the medical equipment provider’s stock worth $2,425,000 after purchasing an additional 192 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.8 %

HOLX opened at $82.40 on Friday. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $84.67. The firm has a 50-day moving average price of $80.63 and a two-hundred day moving average price of $77.01. The stock has a market capitalization of $19.23 billion, a PE ratio of 42.04, a PEG ratio of 2.53 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the business posted $0.93 earnings per share. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the topic of several analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 price objective on shares of Hologic in a research note on Friday, August 16th. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday. JPMorgan Chase & Co. upped their target price on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Finally, Stephens reissued an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Hologic has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Insider Activity

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 over the last 90 days. 1.75% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.